An aqueous solution for intraoral cleaning via irradiation with ultraviolet ray and/or near-ultraviolet visible ray and/or ray in an 800-900 nm near-infrared region is employed as the hydrogen peroxide aqueous solution, wherein a concentration of hydrogen peroxide is 1 w/v % to 7 w/v %, and a concentration of a hydrogen peroxide stabilizer is 81 ppm (mg/L) or less in the aqueous solution.

An aqueous solution for intraoral cleaning via irradiation with ultraviolet ray and/or near-ultraviolet visible ray and/or ray in an 800-900 nm near-infrared region is employed as the hydrogen peroxide aqueous solution, wherein a concentration of hydrogen peroxide is 1 w/v % to 7 w/v %, and a concentration of a hydrogen peroxide stabilizer is 81 ppm (mg/L) or less in the aqueous solution.

The present invention relates to a new multifunctional debridement and/or antifouling composition comprising H.sub.2O.sub.2 at a final concentration of between 0.1-5% v/v, and a composite hydrogel formulation comprising pluronic acid at a concentration of 10-40% w/v, wherein the composition is in liquid form at room temperature. The composition disclosed herein is antimicrobial and/or anti-inflammatory and is particular useful in periimplantitis treatment and implant health maintenance, in periodontitis and periodontal health and in wound care and chronic ulcer care.

The present invention relates to a new multifunctional debridement and/or antifouling composition comprising H.sub.2O.sub.2 at a final concentration of between 0.1-5% v/v, and a composite hydrogel formulation comprising pluronic acid at a concentration of 10-40% w/v, wherein the composition is in liquid form at room temperature. The composition disclosed herein is antimicrobial and/or anti-inflammatory and is particular useful in periimplantitis treatment and implant health maintenance, in periodontitis and periodontal health and in wound care and chronic ulcer care.

Provided is a kit or system (100) for preparing a peroxide composition with increased viscosity with a pH in the range of 7 to 12 in an almost instantaneous method. For example, the kit or system may be used to provide an almost instantly obtainable (hydro)gelled peroxide composition. The system comprises a first aqueous composition (102) comprising a peroxide agent. The first aqueous composition has a first pH of less than 7. The system further comprises a second composition (104) comprising a basic agent. The second composition is separate from the first aqueous composition. A pH induced thickener is included in the kit or system separate from the second composition. The peroxide composition is obtainable by combining the parts of the kit or system. The pH induced thickener is capable of increasing the viscosity of the peroxide composition upon subjecting it to the pH in the range of 7 to 12. The kit or system has sufficient basic agent for the peroxide composition to cause the pH in the range of 7 to 12. A method for preparation and use of the kit or system is also provided.

Provided is a kit or system (100) for preparing a peroxide composition with increased viscosity with a pH in the range of 7 to 12 in an almost instantaneous method. For example, the kit or system may be used to provide an almost instantly obtainable (hydro)gelled peroxide composition. The system comprises a first aqueous composition (102) comprising a peroxide agent. The first aqueous composition has a first pH of less than 7. The system further comprises a second composition (104) comprising a basic agent. The second composition is separate from the first aqueous composition. A pH induced thickener is included in the kit or system separate from the second composition. The peroxide composition is obtainable by combining the parts of the kit or system. The pH induced thickener is capable of increasing the viscosity of the peroxide composition upon subjecting it to the pH in the range of 7 to 12. The kit or system has sufficient basic agent for the peroxide composition to cause the pH in the range of 7 to 12. A method for preparation and use of the kit or system is also provided.

An antimicrobial composition includes an aqueous and/or ethanolic solution of iodine and hydrogen peroxide, which is acidified. The acidifying agent may be aspirin, hydrochloric acid, or other acidic agent tolerable to the body. The composition may also include a witch hazel extract, or alternately hamamelitannin, gallic acid, or other components thereof that effect quorum signaling inhibition that blocks and erodes microbe-induced biofilm on cellular and device surfaces. Acetohydroxamic acid may be combined with the composition as a counter to microbe-induced alkalinization, particularly in urine. Moreover, a metal, halogen, and combinations of these, such as a silver colloid, may be added as a secondary microbicidal agent. The antimicrobial composition may be applied topically to or instilled through an indwelling urinary catheter or applied as a device surface-coating on other medical devices.

An antimicrobial composition includes an aqueous and/or ethanolic solution of iodine and hydrogen peroxide, which is acidified. The acidifying agent may be aspirin, hydrochloric acid, or other acidic agent tolerable to the body. The composition may also include a witch hazel extract, or alternately hamamelitannin, gallic acid, or other components thereof that effect quorum signaling inhibition that blocks and erodes microbe-induced biofilm on cellular and device surfaces. Acetohydroxamic acid may be combined with the composition as a counter to microbe-induced alkalinization, particularly in urine. Moreover, a metal, halogen, and combinations of these, such as a silver colloid, may be added as a secondary microbicidal agent. The antimicrobial composition may be applied topically to or instilled through an indwelling urinary catheter or applied as a device surface-coating on other medical devices.

The present invention identifies AKR1C1 as the first lipedema-associated gene. The invention provides methods for diagnosing or assessing an individual's susceptibility to lipedema by the analysis of the AKR1C1 gene or the expression levels of its product and related metabolites. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lipedema.

The present invention identifies AKR1C1 as the first lipedema-associated gene. The invention provides methods for diagnosing or assessing an individual's susceptibility to lipedema by the analysis of the AKR1C1 gene or the expression levels of its product and related metabolites. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lipedema.